

Pharmaceutical residues removal in a pilot wastewater treatment plant

Tina Kosjek* # §, Ester Heath* and Boris Kompare#

*Department of Environmental Sciences, Jožef Stefan Institute, Ljubljana,
Slovenia

#University of Ljubljana, Faculty for Civil and Geodetic Engineering, Ljubljana,
Slovenia

*Haslauer d.o.o., Zabukovica 87, Griže, Slovenia

§Jožef Stefan International Postgraduate School, Ljubljana, Slovenia



Univerza v Ljubljani



NORMAN workshop, Menorca, Spain, November 27-28, 2006

1

Presentation Outline

Introduction

Experimental

Identification

- Target compounds
- Analytical procedure

Elimination

- Pilot wastewater treatment plant
- Identification of degradation products
- Biomass adaptation

Results and Discussion

Conclusions and Future work



Univerza v Ljubljani



NORMAN workshop, Menorca, Spain, November 27-28, 2006

2

Pharmaceuticals: importance and characteristics

- Indispensable element of modern life
- highly biologically active
- often highly water soluble
- not readily (bio)degradable
→ chemical stability needed for pharmacological action



MOBILITY
IN WATER



Univerza v Ljubljani



NORMAN workshop, Menorca, Spain, November 27-28, 2006

3

Pharmaceuticals: purchase

- **Germany:** human pharmaceuticals **6500 t/year**
(78g per capita per year)
- consumption expected to increase (demographic changes):
 - ✓ growing life expectancy at birth
 - ✓ higher % of old population
- approx. 90% dispensed in retail pharmacies 
 - ✓ 70% prescribed by doctors
 - ✓ 20% bought for self-medication (over-the-counter = OTC drugs)



Univerza v Ljubljani




NORMAN workshop, Menorca, Spain, November 27-28, 2006


4

Pharmaceuticals: characteristics

- metabolism in human body → combination of parent compounds and metabolites → release into aquatic environment
- 2nd phase metabolite → in WWTP often degraded back into parent compound / 1st phase metabolite



testosterone glucuronide



estrone sulfate

- combinations: synergistic / additive effects???



Univerza v Ljubljani



NORMAN workshop, Menorca, Spain, November 27-28, 2006

5

Risks

- **occurrence:**
 - ✓ environmental persistence
 - ✓ high consumption
- **risks** deriving from **chronic low-dosage exposure** to pharmaceutical residues: **not yet evaluated**
- reported aquatic **toxicity:**
 - ✓ estrogenic effects of contraceptive drugs;
 - ✓ antibiotic resistance;
 - ✓ vulture decline from diclofenac



Univerza v Ljubljani




NORMAN workshop, Menorca, Spain, November 27-28, 2006

6

Exposure

Sources of pharmaceuticals in the environment



Univerza v Ljubljani



NORMAN workshop, Menorca, Spain, November 27-28, 2006

7

Goals of Our Study

Criteria for selection of pharmaceuticals: widespread use in Central Europe

Members of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)

Relatively well known acute toxicity

Poorly investigated chronic effects of low dosages; possible synergistic effects

PRESENCE IN THE ENVIRONMENT?????

PERSISTENCE IN THE ENVIRONMENT?????



Univerza v Ljubljani



NORMAN workshop, Menorca, Spain, November 27-28, 2006

8

Pharmaceutical Residues in Slovene Surface Waters

sample	Date of sampling	koncentracija (ng L ⁻¹)			
		naproksen	diklofenak	ketoprofen	ibuprofen
KRKA 1	jul.04	-	-	-	-
	sep.04	-	-	-	-
	apr.05	-	-	-	-
KRKA 2	jul.04	310	280	-	-
	sep.04	60	50	-	-
	apr.05	280	310	120	-
LJUBLJANICA 1	jul.04	-	-	-	-
	sep.04	-	-	-	-
LJUBLJANICA 2	jul.04	70	-	-	-
	sep.04	-	-	-	-
SAVA	jul.04	80	10	-	-
	sep.04	-	-	-	-
MURA	jul.04	50	40	-	-
DRAVA 1	jul.04	50	30	-	-
	sep.04	-	-	-	-
DRAVA 2	jul.04	20	30	-	-
	sep.04	40	-	-	-
PŠATA	jul.04	20	-	-	-

T. Kosjek, E. Heath, A. Krbavčič; Environment International 31 (2005) 679-685.



Univerza v Ljubljani



NORMAN workshop, Menorca, Spain, November 27-28, 2006

9

Pharmaceutical Residues in sediments

	River water (14.4.2005) (ng L ⁻¹)		Sediment (14.4.2005) (ng g ⁻¹)	
	River Krka (upstream)	River Krka (downstream the pharmaceutical factory and urban area)	River Krka (upstream)	River Krka (downstream the pharmaceutical factory and urban area)
ibuprofen	udl	udl	udl	udl
naproxen	udl	308	udl	26
ketoprofen	udl	281	udl	320
diclofenac	udl	89	udl	udl



Univerza v Ljubljani



NORMAN workshop, Menorca, Spain, November 27-28, 2006

10

Hypothesis

Pharmaceutical residues have been reported in surface, ground and drinking waters.

How to diminish / prevent their entrance into the environment?

A. proper handling of excess / expired pharmaceuticals

B. diminishing the discharge of pharmaceuticals at the point-sources of pollution:

- municipal & hospital WWTP
- effluents from pharmaceutical industry



Univerza v Ljubljani




NORMAN workshop, Menorca, Spain, November 27-28, 2006


11

Experimental

Acidic pharmaceuticals



Blood lipid regulator (active metabolite)



Univerza v Ljubljani



NORMAN workshop, Menorca, Spain, November 27-28, 2006

12

Pharmaceuticals: potential environmental effects

Nonsteroidal antiinflammatory drugs (NSAIDs):

representatives Diclofenac (Voltaren®), naproxen, ketoprofen, ibuprofen	side effects Abdominal pain, gastrointestinal reflux, asthma, prolonged blood coagulation
---	---

- ✓ diclofenac: **resistant to biodegradation**
- ✓ reported **environmental toxicity**
- ✓ applied in high amounts; **available without prescription**
- ✓ interactions with numerous pharmaceuticals: syneristic, additive, toxic effects



Univerza v Ljubljani



NORMAN workshop, Menorca, Spain, November 27-28, 2006

13

Experimental


Analytical procedure for determination of pharmaceuticals in water samples (1)

1. Sample Preparation



A. sample pre-preparation (acidification, filtration,...)

B. internal standard addition:


d3-ibuprofen



mecoprop



ibuprofen



clofibric acid



Univerza v Ljubljani



NORMAN workshop, Menorca, Spain, November 27-28, 2006



14

Experimental

Analytical procedure for determination of pharmaceuticals in water samples (2)

C. solid phase extraction (SPE): Strata™ X, Oasis® HLB extraction cartridges

D. derivatisation: **MSTFA** (N-methyl-N-trimethylsilyl trifluoroacetamide), **MTBSTFA** (N-methyl-N-(tert-butyldimethylsilyl) trifluoroacetamide)



Univerza v Ljubljani



NORMAN workshop, Menorca, Spain, November 27-28, 2006

15

Experimental

Analytical procedure for determination of pharmaceuticals in water samples (3)

2. Chemical Analysis: GC-MSD

A. separation: gas chromatography: HP 6890 GC, capillary column Zebron ZB-5 (Phenomenex, 30m x 0,25mm x 0,25um); carrier gas: He; velocity 37 cm s⁻¹; injection: "splitless" mode; T injector: 250°C; volume inj.: 1μL

B. identification: mass spectrometry

- quantitative determination: sim mode with characteristic ion fragments (internal standard addition). m/z for MTBSTFA derivatisation: ibuprofen m/z = 263, ibuprofen-D3 m/z = 266, naproxen m/z = 287, ketoprofen m/z = 311, diclofenac m/z = 352 & 354
- identification of degradation products: scan mode



Univerza v Ljubljani




NORMAN workshop, Menorca, Spain, November 27-28, 2006

16

Persistence / removal in PWWTP?

PWWTP design

- aerobic and anaerobic / anoxic segment
- continuous supply with pharmaceuticals at flow rate 2 L day^{-1}
- residence time = 48 hours
- reactor volume = 4 L
- active sludge origin: Slovene municipal wastewater treatment plant
- sampling: influent & effluent



Univerza v Ljubljani



NORMAN workshop, Menorca, Spain, November 27-28, 2006

17

Persistence / removal in PWWTP?

Pilot wastewater treatment plant (PWWTP)

- R0 = blank
- R1 = $0,05 \text{ mg L}^{-1}$ of each pharmaceutical
- R2 = $0,005 \text{ mg L}^{-1}$ of each pharmaceutical

$$\% \text{ eff.} = \frac{(c_{X-\text{INF}} - c_{X-\text{EFF}})}{c_{X-\text{INF}}} \times 100$$

- PWWTP operation: since June 2004
- Sampling: first 6 months on a weekly basis, later on a monthly basis



Univerza v Ljubljani



NORMAN workshop, Menorca, Spain, November 27-28, 2006

18

Results

Removal of pharmaceuticals in PWTP

PHARMACEUTICAL	REACTOR	AV. REMOVAL RATE (%)	STDEV
IBUPROFEN	R1	95,6	4
	R2	96,4	6
NAPROXEN	R1	96,1	3
	R2	88,8	8
KETOPROFEN	R1	94,9	5
	R2	90,3	6
DICLOFENAC	R1	54,4	23
	R2	56,4	36
CLOFIBRIC ACID	R1	24,2	22
	R2	29,5	20

> High and constant removal of ibuprofen, naproxen and ketoprofen


> Poor and variable removal of diclofenac and clofibrac acid

> Removal mechanisms: (bio)degradation and/or adsorption



Results

Identification of degradation products (1)




- trimethylsilyl esters of residual pharmaceuticals and internal standard
- degradation products are signposted



Results

Identification of degradation products (2)

Mass spectrum diclofenac's degradation product :
 (2,6-dichlorophenyl)-1,3-dihydro-2H-indol-2-one




NORMAN workshop, Menorca, Spain, November 27-28, 2006

21


Results

Identification of degradation products (3)


Diclofenac's degradation products:



2-((2,6-dichlorophenyl)-amino) benzyl alcohol




methyl ether of 2-((2,6-dichlorophenyl)-amino) benzyl alcohol




1-(2,6-dichlorophenyl)-1,3-dihydro-2H-indol-2-one

Parent compound:




Naproxen's degradation product:



(6-methoxy-2-naphthyl) ethanol

Parent compound:



Univerza v Ljubljani



HASLAUER


NORMAN workshop, Menorca, Spain, November 27-28, 2006

22

Results

Study of biomass adaptation (1)

- Two years of continuous operation ... → adaptation of the biomass???
- **T-RFLP** (Terminal-Restriction Fragment Length Polymorphism) analysis: differences in bacterial community between R1 compared to R0 and R2 model reactors



Univerza v Ljubljani

HASLAUER
INSTRUMENTS & SYSTEMS G.M.B.H.
92200 Dorn - Dornbirn, Austria



NORMAN workshop, Menorca, Spain, November 27-28, 2006


23

Results

Study of biomass adaptation (2)

- Replication of R1 biomass to:
 - model reactor operating under same concentration 50 µg/L: R1r/50
 - 4-times higher conc., 200 µg/L: R1r/200,
 - 10-times higher conc., 500 µg/L: R1r/500)

→ immediate acclimatization of R1r/50



Univerza v Ljubljani

HASLAUER
INSTRUMENTS & SYSTEMS G.M.B.H.
92200 Dorn - Dornbirn, Austria



NORMAN workshop, Menorca, Spain, November 27-28, 2006

24

Future work

- optimisation of WWTP operation to improve removal of clofibric acid and diclofenac (e.g. integration of anaerobic segment)
- additional methods to improve removal of persistent compounds, e.g. ozonation/H₂O₂, UV treatment, etc...
- determination of removal mechanism of the selected pharmaceutical residues
- influence of light (photolysis) on the removal efficiency



Univerza v Ljubljani



NORMAN workshop, Menorca, Spain, November 27-28, 2006

25

Future work

- wider range of pharmaceuticals involved into the (bio)degradation study (carbamazepine, estrogenic compounds, antitumor drugs,...)
- toxicity (ecotoxicity, genotoxicity, cytotoxicity,...) of pharmaceuticals and their degradation products in collaboration with National Institute of Biology, Slovenia
- the new-developed treatment procedure on larger scale pilot wastewater treatment plant



Univerza v Ljubljani



NORMAN workshop, Menorca, Spain, November 27-28, 2006

26

Acknowledgements

For financial support:

- Centre of Excellence Environmental Technologies, Ministry of Higher Education, Science and Technology, Slovenia (Contract No.: 3211-05-000184)
- Slovenian research agency (Programme groups P1-0143 and P2-0180, Project L1-6552)



National Institute of Biology, Slovenia

- Photodegradation studies: Dr. Oliver Bajt (Marine Biological Station, Piran, Slovenia)
- Microbial community: Prof. dr. Ines Mandič Mulec and coworkers



Univerza v Ljubljani



NORMAN workshop, Menorca, Spain, November 27-28, 2006

27